HealthDay News — For patients with diabetes, preadmission selective serotonin reuptake inhibitor (SSRI) use is associated with increased risk of stroke mortality, according to a study published in the Journal of Internal Medicine.
Morten Würtz, MD, PhD, from Aarhus University Hospital in Denmark, and colleagues examined the correlation between preadmission SSRI use and mortality in patients with diabetes who were hospitalized due to stroke. Patients with diabetes from Denmark with first-time stroke-related hospitalizations and subsequent mortality were identified from population-based medical databases (12 620 patients). SSRI use was categorized as current, former, or nonuse based on redeemed prescriptions.
The researchers found that 30-day stroke mortality was 15.8% among SSRI nonusers (10.4% for ischemic stroke, 41.8% for intracerebral stroke, and 27.3% for subarachnoid hemorrhage). Thirty-day stroke-mortality was 23.3% among current SSRI users (17.1% for ischemic stroke, 50.7% for intracerebral hemorrhage, and 28.6% for subarachnoid hemorrhage). Compared with nonuse, current SSRI use correlated with increased 30-day stroke mortality (adjusted mortality rate ratio [MRR], 1.3), with the highest risk for new users (MMR, 1.5). Increased mortality due to ischemic stroke was the driver behind overall stroke mortality, with adjusted MRRs of 1.3 and 1.7 for current and new users, respectively.
“In patients with diabetes, preadmission SSRI use was associated with increased mortality following ischemic stroke, compared with nonuse,” the authors write.
Various companies, including Novo Nordisk, provided research grants to Aarhus University.
Würtz M, Schmidt M, Grove EL, Horváth-puhó E, Christiansen CF, Sørensen HT. Preadmission use of selective serotonin reuptake inhibitors and short-term mortality in diabetic patients hospitalized due to stroke. J Intern Med. 2016; doi:10.1111/joim.12512.